Latest Biotech News

Thermo Fisher Scientific agreed to acquire Clario for $8.8 billion to expand its clinical‑trial data, patient‑centric services, and digital capabilities within its Laboratory Products and...

Qiagen announced it will acquire Parse Biosciences for $225 million upfront plus up to $55 million in milestones, marking a strategic move into scalable single‑cell genomics. Parse’s...

Colossal Biosciences said it has acquired Viagen Pets & Equine, a cloning and reproductive services company that maintains a biobank spanning more than 40 species, including endangered animals....

Azalea Therapeutics, a spinoff from Jennifer Doudna’s lab, launched with $82 million to develop single‑dose, in‑vivo CAR‑T approaches that convert patients’ immune cells directly inside the body....

Nautilus Biotechnology installed its single‑molecule protein analysis system at the Buck Institute for Research on Aging as the first external customer deployment, enabling targeted studies of tau...

Arena BioWorks, a Boston research institute launched in 2024 with $500 million from a group of billionaire backers, confirmed an abrupt shutdown after investors cited deteriorating biotech macro...

Roche signed a strategic collaboration and licensing agreement with Manifold Bio to develop next‑generation brain shuttles designed to ferry therapeutic payloads across the blood‑brain barrier....

George Tidmarsh resigned as director of the FDA’s Center for Drug Evaluation and Research after being placed on administrative leave amid a Department of Health and Human Services probe into...

UniQure said the FDA signaled it no longer regards data from the company’s Phase I/II AMT-130 program versus an external control as sufficient to support a Biologics License Application, throwing...

Metsera’s board declared Novo Nordisk’s latest proposal a superior proposal after Novo raised its bid to as much as $10 billion, setting off swift legal retaliation from Pfizer. Pfizer filed...

Sarepta Therapeutics announced its ESSENCE Phase III confirmatory trial for two exon‑skipping antisense oligonucleotides failed to meet the study’s primary endpoint, a blow to drugs marketed under...

Caribou Biosciences reported data suggesting its off‑the‑shelf CAR‑T candidate delivers deep, durable remissions in advanced B‑cell lymphoma, with response rates approaching benchmarks set by...

Nautilus Biotechnology installed its single‑molecule protein analysis platform at the Buck Institute to study tau proteoforms in Alzheimer’s and other neurodegenerative diseases. Buck is the first...

OneOme, the Mayo Clinic spinoff known for the RightMed pharmacogenomics test, announced a sudden closure of operations citing financial challenges. The Minneapolis‑based company will stop...

Thermo Fisher Scientific agreed to acquire clinical trial data firm Clario for $8.8 billion, a deal that will expand Thermo Fisher’s digital offerings across trial operations and data management....

Roche signed a strategic collaboration and license deal with Manifold Bio to develop next‑generation brain shuttles, paying an upfront $55 million and structuring a partnership that could exceed...

Blackstone Life Sciences agreed to purchase a stake in Merck’s Trop‑2 antibody‑drug conjugate program, paying roughly $700 million to underwrite development and share future royalty streams....

Novo Nordisk increased its takeover proposal for obesity biotech Metsera, lifting its offer to as much as $10 billion and reshaping the competitive auction for a leading obesity-platform company....

George Tidmarsh, the director of the FDA’s Center for Drug Evaluation and Research (CDER), resigned following reports of administrative leave and a Health and Human Services probe into his...

UniQure disclosed that the FDA now signals it may no longer accept AMT‑130’s Phase I/II data — based on comparisons to an external control — as sufficient evidence to support a Biologics License...